We are live on ! Find out more
MP

Mangrove Partners Portfolio holdings

AUM $1.24B
1-Year Est. Return 41.74%
This Fund
S&P 500
This Quarter Est. Return
+24.95%
1 Year Est. Return
+41.74%
3 Year Est. Return
+169.22%
5 Year Est. Return
+150.23%
10 Year Est. Return
+417.9%
AUM
$1.44B
AUM Growth
-$42.2M
Cap. Flow
-$133M
Cap. Flow %
-9.26%
Top 10 Hldgs %
29.23%
Holding
202
New
26
Increased
19
Reduced
11
Closed
39

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$34.8M
2
X
US Steel
X
+$34.6M
3
AGR
Avangrid, Inc.
AGR
+$32.7M
4
WS icon
Worthington Steel
WS
+$26.7M
5
CTLT
CATALENT, INC.
CTLT
+$25M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$64.7M
2
IJR icon
iShares Core S&P Small-Cap ETF
IJR
+$62.7M
3
WFRD icon
Weatherford International
WFRD
+$56.8M
4
DELL icon
Dell
DELL
+$37.5M
5
SPLK
Splunk Inc
SPLK
+$32M

Sector Composition

Rank Sector Weight
1 Healthcare 12.86%
2 Consumer Discretionary 12.47%
3 Financials 11.09%
4 Industrials 7.54%
5 Communication Services 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBC icon
1
MasterBrand
MBC
$1.09B
$50.4M 3.5%
2,687,175
– –
AER icon
2
AerCap
AER
$23.9B
$47.8M 3.32%
550,014
– –
ACI icon
3
Albertsons Companies
ACI
$5.4B
$45.8M 3.19%
2,138,156
+962,587
+82% +$20.6M
JXN icon
4
Jackson Financial
JXN
$8.32B
$45.8M 3.18%
691,869
– –
X
5
DELISTED
US Steel
X
$44.4M 3.09%
1,089,169
+756,705
+228% +$34.6M
ATMU icon
6
Atmus Filtration Technologies
ATMU
$4.37B
$40.8M 2.84%
1,264,700
+142,484
+13% +$3.41M
TEVA icon
7
Teva Pharmaceuticals
TEVA
$35.9B
$39M 2.71%
+2,762,154
New +$34.8M
AGR
8
DELISTED
Avangrid, Inc.
AGR
$36.5M 2.54%
+1,001,922
New +$32.7M
ENVA icon
9
Enova International
ENVA
$5.91B
$35.5M 2.47%
565,008
– –
EMBJ
10
Embraer S.A. ADS
EMBJ
$11.6B
$34.5M 2.4%
1,294,313
– –
VAL icon
11
Valaris
VAL
$5.51B
$31.6M 2.2%
419,899
– –
WS icon
12
Worthington Steel
WS
$1.8B
$31.5M 2.19%
+878,860
New +$26.7M
GOOGL icon
13
Alphabet (Google) Class A
GOOGL
$3.91T
$30.7M 2.13%
203,235
– –
LAUR icon
14
Laureate Education
LAUR
$5.18B
$29.9M 2.08%
2,049,057
– –
MREO
15
Mereo BioPharma
MREO
$45.9M
$28.9M 2.01%
8,752,893
– –
TSEM icon
16
Tower Semiconductor
TSEM
$26.4B
$27.2M 1.89%
813,043
– –
CTLT
17
DELISTED
CATALENT, INC.
CTLT
$26.1M 1.81%
+461,981
New +$25M
BRSL
18
Brightstar Lottery PLC
BRSL
$1.91B
$26M 1.8%
1,149,095
– –
OI icon
19
O-I Glass
OI
$1.39B
$25.7M 1.79%
1,550,977
+540,836
+54% +$8.55M
LLYVK icon
20
Liberty Live Group Series C
LLYVK
$9.11B
$25.7M 1.79%
586,534
– –
IJR icon
21
iShares Core S&P Small-Cap ETF
IJR
$109B
$24.7M 1.72%
223,300
-590,221
-73% -$62.7M
AMED
22
DELISTED
Amedisys
AMED
$24.4M 1.7%
264,826
+95,192
+56% +$8.92M
JNPR
23
DELISTED
Juniper Networks
JNPR
$23.4M 1.63%
+632,678
New +$23.1M
SSNC icon
24
SS&C Technologies
SSNC
$17.8B
$21M 1.46%
326,750
– –
UBS icon
25
UBS Group
UBS
$170B
$20.3M 1.41%
659,546
– –
1
2 3 4 5

Similar funds

GX
Greylock XIV Menlo Park, California $1.24B AUM
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Mangrove Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Mangrove Partners held 202 positions worth $1.44B, down 2.8% from $1.48B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Mangrove Partners withdrew a net $133M in Q1 2024, closing 39 positions and reducing 11 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $64.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.6% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Mangrove Partners opened a new position in Teva Pharmaceuticals worth $39M.

  • Mangrove Partners's largest Q1 2024 buy was Teva Pharmaceuticals: 2,762,154 shares worth $39M.
  • Mangrove Partners added most to US Steel in Q1 2024, an estimated $34.6M increase.
  • Mangrove Partners's biggest Q1 2024 reduction was iShares Core S&P Small-Cap ETF, cutting an estimated $62.7M.
  • Mangrove Partners fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $64.7M.
  • Mangrove Partners's ten largest holdings make up 29% of its $1.44B portfolio in Q1 2024.
  • Mangrove Partners opened 26 new positions and closed 39 in Q1 2024.
  • Mangrove Partners's portfolio value fell 2.8% quarter-over-quarter to $1.44B.

Based on Mangrove Partners's 13F filing for Q1 2024, filed 15 May 2024.